General Assembly Proposed Bill No. 766
January Session, 2021 LCO No. 2017
Referred to Committee on INSURANCE AND REAL ESTATE
Introduced by:
SEN. ANWAR, 3rd Dist.
AN ACT CONCERNING REQUIRED HEALTH INSURANCE AND
MEDICAID COVERAGE FOR BRAND-NAME PRESCRIPTION DRUGS.
Be it enacted by the Senate and House of Representatives in General
Assembly convened:
1 That the general statutes be amended to require health carriers and
2 Medicaid to provide coverage, without substitution, for a brand-name
3 prescription drug prescribed by a prescribing practitioner if: (1) The
4 prescribing practitioner (A) specifies, in writing or by telephonic or
5 other electronic means, (i) that there shall be no substitution for such
6 drug and such drug, and the prescribed dosage of such drug, is
7 medically necessary despite the availability of a therapeutically
8 equivalent covered generic prescription drug, (ii) the basis for such
9 prescribing practitioner's conclusion that such drug, and the prescribed
10 dosage of such drug, is medically necessary despite the availability of a
11 therapeutically equivalent covered generic prescription drug; and (2)
12 the phrase "brand medically necessary" appears, and the prescribing
13 practitioner requests that such phrase appear, on the prescription and,
14 if the prescribing practitioner requests by telephonic or electronic means
15 that such phrase appear on the prescription, a written certification in
LCO No. 2017 1 of 2
 Proposed Bill No. 766
16 such prescribing practitioner's handwriting bearing such phrase is sent
17 to the dispensing pharmacy not later than ten days after the date of such
18 prescription.
Statement of Purpose:
To modify certain provisions requiring health insurance and Medicaid
coverage for brand-name prescription drugs.
LCO No. 2017 2 of 2